Baloxavir

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Baloxavir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
    • Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.

NON-FDA APPROVED USES

  • Treatment of influenza in individuals at high risk for influenza-related complications

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
    • Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.

NON-FDA APPROVED USES

  • Treatment of influenza in individuals at high risk for influenza-related complications

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: May 8, 2020